VMQ StocksFor the value investor looking to harness academic research in
an actively managed portfolio
Bits and BipsNewsletter delivering insights on linking traditional finance, macro trends and cryptocurrency opportunities to help investors build stronger, more diversified portfolios.
All premium products come with free basic membership.
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company’s lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Learn more about Acurx Pharmaceuticals Inc's (ACXP) stock grades for Momentum, Growth and Estimate Revisions and determine whether this Biotechnology & Medical Research stock meets your investment needs.
Jenna Brashear
Financial Summary
Share Statistics
ACXP
Industry Median
Percentile (All Stocks)
Market Cap (Mil)
$6.2
$252.6
5%
Shares Out (Mil)
2.7
52.3
9%
Institutional Ownership
79.0%
92.1%
48%
Float (Mil)
4.2
40.2
10%
Beta
-2.09
0.95
0%
Avg Daily Volume (000s)
74
455
32%
Price Change (52-week)
(78.2%)
52.9%
7%
Growth
ACXP
Industry Median
Percentile (All Stocks)
Sales (5yr)
na
13.6%
na
Net Income (5yr)
(11.7%)
(9.9%)
27%
EPS (5yr)
18.6%
16.0%
65
Dividends (5yr)
na
0.0%
na
Cash Flow (5yr)
2.8%
(15.6%)
66%
Estimates
Qtrly
Current Fiscal Year
Next Fiscal Year
# of Estimates
2
2
2
Current EPS
($0.435)
($1.970)
($2.130)
Month Ago EPS
($0.435)
($1.970)
($2.130)
# Rev Up
1
0
0
# Rev Down
0
1
1
Three Months Ago EPS
($0.555)
($2.390)
($2.200)
Year/Year Chg
(29.6%)
(62.9%)
(54.8%)
Financials
ACXP
Industry Median
Percentile (All Stocks)
Sales (TTM) (Mil)
na
$38
na
Net Income (TTM) (Mil)
($8)
($43)
31%
EPS (TTM)
($3.889)
($1.600)
9%
Operating Cash Flow (TTM) (Mil)
($6)
($31)
23%
Net Cash Flow (TTM) (Mil)
na
$5
na
Long-Term Debt (Q1) (Mil)
$0
$5
0%
Enterprise Value (Q1) (Mil)
($3)
$180
3%
Valuation
ACXP
Industry Median
Percentile (All Stocks)
P/B
0.70
2.56
14%
P/E
na
19.0
na
Dividend Yield
na
0.0%
na
PEG (5yr hist)
na
0.9
na
Ratios
ACXP
Industry Median
Percentile (All Stocks)
Gross Margin
na
63.8%
na
Net Margin
na
(67.3%)
na
ROA
(104.5%)
(49.8%)
5%
ROE
(160.8%)
(55.5%)
6%
Liabilities to Assets
26.5%
30.3%
18%
F-Score
3
3
19%
Acurx Pharmaceuticals, Inc. did not pass any screens on 7/31/2026.
Looking for access to this powerful feature? Take the first step in becoming an A+ Investor today.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors